Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setanaxib in Alport Syndrome
NCT06274489Phase 2Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Alport syndrome comparing Setanaxib with Setanaxib placebo (2 arms). Primary endpoints: Percentage of Patients With Serious Adverse Events at 32 weeks and Percentage of Patients With Treatment-emergent Adverse Events of Special Interest at 32 weeks. Started Nov 2023; status: completed.
02
Drugs
setanaxib
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT06274489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274489.